Navigation Links
State payer mandates to cover cancer trials offer heterogeneous protection for patients
Date:3/2/2010

A 2001 federal law mandates care for Medicare-eligible patients enrolled in clinical trials; however, only 25 state laws cover clinical-trial related medical costs for non-Medicare patients, and these offer less protection than the federal law. A lawyer explains these findings in a special article published online March 2 in the Journal of the National Cancer Institute.

In the United States, participants' costs for routine care and complications from cancer clinical trials are covered by Medicare because of a 2001 Medical Coverage Determination. People not covered by Medicare, however, depend on state insurance mandates with respect to coverage. Few publications have examined state laws regarding insurance coverage for costs of cancer clinical trials, and none have addressed whether such provisions promote scientific and ethical quality.

To address these issues, Patrick L. Taylor, J.D., of the Children's Hospital Boston and Harvard Medical School, reviewed legal data from three nationwide cancer trial databases and from similar databases in each state. State mandates were reviewed for requirements to assure trials' scientific and ethical soundness, whom they covered and omitted, scope, and coverage for participants' research-related injuries in addition to routine care costs.

Taylor found that only 25 states had enacted legislation concerning coverage of cancer clinical trial costs. Among these, most did not expressly require unbiased scientific review or ethical review. About half of them required coverage of only certain kinds of trials, under certain conditions, and very few required publication of results.

"For science and ethics to matter in practice, there will need to be closer, more exact communication between legislators and diverse members of the oncology community, including clinical researchers, on essential policy elements," the author writes.

There appears to be much room for legislative i
'/>"/>

Contact: Caroline McNeil
jncimedia@oxfordjournals.org
301-841-1286
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. First biomarker discovered that predicts prostate cancer outcome
3. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
4. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
5. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
8. Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor
9. Red wine compound shown to prevent prostate cancer
10. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
11. PA Secretary of Public Welfare Responds to Warren State Hospital Closure Rumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... London, England (PRWEB) December 26, 2014 ... to take place March 24-28, 2015 in Rome, Italy ... years' line-up includes workshops on a wide ... insomnia, as well as peak performance training in athletes. ... from around the world. , Biofeedback monitoring allows clients ...
(Date:12/26/2014)... 26, 2014 DW-InductionHeating.com (DaWei Induction Heating ... researching and developing, producing and marketing of a series ... business announces their new series of induction brazing ... the company, induction brazing refers to the ... filler material and heat. The manager says that there ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company ... collection of discounted prom dresses, most of which are ... of the company, the promotion is valid until Jan. ... expand the UK market. , The prom dresses in ... and styles: A-line strapless, empire strapless chiffon, one shoulder, ...
(Date:12/25/2014)... When head lice hits a home or ... to get rid of it while keeping it from taking ... now have the solution right in their neighborhood: Lice ... Troopers provides full spectrum head lice screening and treatment services ... Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... cardiac surgery capability can perform nonemergency angioplasty and stent ... surgery. That is the finding of the nation,s ... just as well having nonemergency angioplasty performed at smaller, ... Results of the study, called the Cardiovascular Patient Outcomes ...
... Mann HealthDay Reporter , MONDAY, Nov. 14 ... injection of a man-made protein might lower levels of ... AMG145 reduced low-density lipoprotein (LDL) cholesterol levels among ... a newly identified cholesterol regulator, PCSK9, which interferes with ...
... in the Princess Margaret Cancer Program have found a promising ... new way. The proof-of-concept research published today in ... discovered that the antibiotic tigecycline targets and destroys leukemia stem ... you think of all the cells in the body as ...
... HealthDay Reporter , MONDAY, Nov. 14 (HealthDay News) ... medications if they,re free, U.S. researchers find. Less than ... prescribed medications, which increases hospitalizations, deaths and costs to the ... eliminating the co-pay fee might entice more patients to take ...
... network led by a Mayo Clinic physician found that stem ... after a person has a heart attack did not improve ... the timing and method of stem cell delivery and provides ... The results were presented this morning at the 2011 Scientific ...
... sufferers, a day can feel like a year and a year ... approved by the U.S. Food and Drug Administration for this condition ... the FDA has taken note. With up to $4.5 million in ... the University of Rochester Medical Center will study different approaches to ...
Cached Medicine News:Health News:Patients fare just as well if their nonemergency angioplasty is performed at hospitals 2Health News:Patients fare just as well if their nonemergency angioplasty is performed at hospitals 3Health News:Shot Might One Day Help Lower Cholesterol 2Health News:Shot Might One Day Help Lower Cholesterol 3Health News:Canadian researchers find potential new leukemia treatment with old antibiotic drug 2Health News:More Heart Attack Patients Take Meds When They Are Free 2Health News:More Heart Attack Patients Take Meds When They Are Free 3Health News:Stem cell study helps clarify the best time for therapy to aid heart attack survivors 2Health News:Stem cell study helps clarify the best time for therapy to aid heart attack survivors 3Health News:FDA funds Rochester researchers to give chronic and acute pain clinical trials a makeover 2Health News:FDA funds Rochester researchers to give chronic and acute pain clinical trials a makeover 3
(Date:12/24/2014)... -- Commonwealth Cornerstone Group (CCG) today announced the completion of an ... help fund the expansion and consolidation of healthcare services provided ... . PHN is the largest federally qualified ... is the largest employer in Sharon,s ... Currently, PHN Sharon offers scattered services out of ...
(Date:12/24/2014)... 24, 2014 Kinex Pharmaceuticals announced today that ... Roswell Park Cancer Institute. KX2-361 (KX02), a ... has shown potent inhibitory activity against a broad panel ... resistant to Temozolomide (T98G), the most widely used chemotherapy ... brain tumor mouse model, KX2-361 consistently clears brain tumors ...
(Date:12/24/2014)... Trade Commission (ITC) issued its final decision in the case ... issued on December 23, the ITC ruled in favor of ... invalid. BMC President, James Xu called ... the ITC,s decision in this case. This victory for us ... beginning on the key patents in the case. ResMed chose ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
... R1626 into phase IIb study, called POLI 1 ... of Roche,s new,investigational drugs for chronic hepatitis C ... given in combination with,PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(TM) ... Association for the Study of the,Liver Disease (AASLD) ...
... MCLEAN, Va., Nov. 1 Science,Applications International Corporation ... awarded a contract extension by the National Institute ... and Infectious,Diseases (DMID), part of the National Institutes ... services. The seven-year cost-plus-fixed-fee contract has an ...
Cached Medicine Technology:Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 2Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 3Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 4Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 5Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 6Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 7SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases 2
... The TOPCON ALE-3600 and ... assure perfectly fit lenses ... and with the convenience ... These lens edgers are ...
Inquire...
... have two choices for finishing. The first choice ... wholesale lab, which meant longer delay to deliver ... order in house, but that meant a substantial ... inventory, more space and employee training. TOPscan Remote ...
... Ergonomic, computer-integrated, flexibility, combined with the ... contemporary styling, make the new Topcon ... highly competitive 21st Century practice environments: ... lane fits comfortably in an 8' ...
Medicine Products: